Provided by Tiger Trade Technology Pte. Ltd.

Esperion Therapeutics

3.69
+0.520016.40%
Post-market: 3.67-0.0200-0.54%16:18 EST
Volume:19.15M
Turnover:69.40M
Market Cap:882.14M
PE:-6.89
High:3.77
Open:3.28
Low:3.28
Close:3.17
52wk High:3.94
52wk Low:0.6925
Shares:239.06M
Float Shares:237.00M
Volume Ratio:2.93
T/O Rate:8.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5358
EPS(LYR):-0.2764
ROE:97.76%
ROA:-5.42%
PB:-1.95
PE(LYR):-13.35

Loading ...

Esperion Therapeutics Reaches Settlement With Dr. Reddy’s, Delaying U.S. Generics of NEXLETOL and NEXLIZET Until 2040

Reuters
·
Oct 03

Esperion Therapeutics - DR. Reddy's Agrees Not to Market Generic Nexletol or Nexlizet Before 2040

THOMSON REUTERS
·
Oct 03

Esperion Reaches Settlement Agreement With Anda Filer, DR. Reddy’s Laboratories, Not to Market Generic Versions of Nexletol® (Bempedoic Acid) and Nexlizet® (Bempedoic Acid and Ezetimibe) Prior to April 19, 2040

THOMSON REUTERS
·
Oct 03

Esperion Therapeutics - Patent Litigation Against Alkem, Aurobindo Pharma, Msn, Renata, Sandoz Is Ongoing

THOMSON REUTERS
·
Oct 03

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040

GlobeNewswire
·
Oct 03

Esperion price target raised to $9 from $7 at Cantor Fitzgerald

TIPRANKS
·
Sep 26

Citizens JMP Sticks to Its Buy Rating for Esperion (ESPR)

TIPRANKS
·
Sep 25

Esperion Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 19

Esperion Partner Otsuka Receives Approval for Nexletol in Japan

MT Newswires Live
·
Sep 19

Esperion Therapeutics Inc - Eligible for Sales Milestones and Royalties in Japan

THOMSON REUTERS
·
Sep 19

Esperion Partner Otsuka Receives Regulatory Approval to Market Nexletol® in Japan for the Treatment of Hypercholesterolemia

THOMSON REUTERS
·
Sep 19

BRIEF-Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias

Reuters
·
Aug 29

Esperion Therapeutics Inc - Bempedoic Acid Recommended for Patients Unable to Take Statin Therapy to Achieve Ldl-C Goal. Class I, Level B

THOMSON REUTERS
·
Aug 29

Esperion Therapeutics to Participate in Cantor Global Healthcare Conference in New York

Reuters
·
Aug 26

Esperion to Participate in Upcoming September Investor Conferences

GlobeNewswire
·
Aug 26

HLS Therapeutics Reports 21% Q2 Adjusted EBITDA Growth and 83% Increase in Cash from Operations; U.S. Clozaril Sales Up 1%

Reuters
·
Aug 14

Esperion Therapeutics Delays Q2 Financial Report Due to Identified Errors

Reuters
·
Aug 12

Esperion Therapeutics Announces Inducement Grants for New Employees Under NASDAQ Rule 5635(c)(4)

Reuters
·
Aug 08

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 08

Esperion Therapeutics Shares Rise After Narrower-Than-Expected Loss, Revenue Beat in Q2

MT Newswires Live
·
Aug 06